Novo Nordisk

FDA Approves Novo Nordisk’s Rybelsus® as the First Oral GLP-1 Therapy to Reduce Cardiovascular Risk in Adults with Type 2 Diabetes

FDA Approves Novo Nordisk’s Rybelsus® as the First Oral GLP-1 Therapy to Reduce Cardiovascular Risk in Adults with Type 2 Diabetes

12 hours ago

2 min read

Novo Nordisk to Acquire Akero Therapeutics in $5.2 Billion Deal to Expand Liver Disease Portfolio

Novo Nordisk to Acquire Akero Therapeutics in $5.2 Billion Deal to Expand Liver Disease Portfolio

11 Oct 2025

2 min read

Ozempic Shows 23% Lower CV Risk Than dulaglutide in Real-World Study

Ozempic Shows 23% Lower CV Risk Than dulaglutide in Real-World Study

19 Sep 2025

2 min read

Read More

Voice Of HealthCare

vohnetwork.com